Gilead Sciences. Very interesting in all areas. COMPANY Gilead Sciences Inc. INDUSTRY Biotechnology TYPE Public Company TICKER NasdaqGS:GILD

Size: px
Start display at page:

Download "Gilead Sciences. Very interesting in all areas. COMPANY Gilead Sciences Inc. INDUSTRY Biotechnology TYPE Public Company TICKER NasdaqGS:GILD"

Transcription

1 Simply Wall St provides a completely new visual way to invest in the stock market. To see other infographic reports like this one for Apple check out simplywall.st. Very interesting in all areas. COMPANY Inc. INDUSTRY Biotechnology TYPE Public Company TICKER NasdaqGS:GILD, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. sciences 1/20

2 10/30/2015 stock analysis infographic Simply Wall St COMPETITORS Johnson & Johnson Pfizer Merck Amgen Allergan Bristol-Myers Squibb GlaxoSmithKline Medtronic sciences 2/20

3 10/30/2015 stock analysis infographic Simply Wall St VALUE 's value based on future cash flows and its price relative to the stock market. VALUE BASED ON FUTURE CASH FLOWS The estimated value of shares based on future cash flows discounted to their present value. Learn more. Future cash flow value Current share price Undervalued About right $108 $124 CURRENT DISCOUNT 13% Share price is $ vs Future cash flow value of $ CURRENT DISCOUNT CHECKS 's share price is below the future cash flow value, but not at a significant discount (< 20%). 's share price is below the future cash flow value, but not at a substantial discount (< 40%). sciences 3/20

4 10/30/2015 stock analysis infographic Simply Wall St PRICE RELATIVE TO MARKET The relative price of shares compared to stock market averages. PRICE BASED ON PAST EARNINGS PRICE BASED ON EXPECTED GROWTH Good value ($) Overvalued ($$$) $ $$ $$$ PE 12.9x Pharma and Biotech industry average PEG 0.3x Good value based on earnings compared to the Pharma and Biotech industry average. Good value based on expected growth. Good value based on earnings compared to the overall market. PRICE BASED ON VALUE OF ASSETS $$ $$$ $ PB 12x Pharma and Biotech industry average Overvalued based on assets compared to the Pharma and Biotech industry average. sciences 4/20

5 10/30/2015 stock analysis infographic Simply Wall St FUTURE PERFORMANCE 's expected performance in the next 1 to 3 years, based on estimates from 17 analyst(s). 49% Expected earnings growth over 3 years. Are 's annual earnings growth expected to exceed 6.4% over the next 3 years? After 1 year After 3 years 1 & 3 YEAR ESTIMATED GROWTH IN EARNINGS 42.5% Low risk savings rate + inflation (6.4% pa) 48.7% 20.5% 6.4% + 1 year + 3 years PAST AND FUTURE EARNINGS PER SHARE $20 USD $ Historical Range of past estimates Analyst's Estimate Range of estimates sciences 5/20

6 10/30/2015 stock analysis infographic Simply Wall St ANALYSTS GROWTH EXPECTATIONS $40B USD Actual Estimated $ Revenue Cash Flow Profit 2 YEAR GROWTH CHECK x1.5? Which of the these is expected to increase by over 50% in 2 year's time? Revenue Cash flow Profit PERFORMANCE IN 3 YEARS is expected to perform strongly, Return on Equity in 3 years is estimated to be above 20%. +3 years 40.96% Return on Equity Pharma and Biotech IMPROVEMENT & RELATIVE TO INDUSTRY Expected to be above the Pharma and Biotech industry average. A decline in 's performance is expected over the next 3 years. sciences 6/20

7 10/30/2015 stock analysis infographic Simply Wall St PAST PERFORMANCE 's performance over the past 5 years. PAST EARNINGS GROWTH EARNINGS GROWTH ANALYSIS 's earnings growth has exceeded the industry average over the past year. 90.6% 32.7% 18.1% 1 year 5 year annual average Pharma and Biotech industry 1 year average 's 1 year earnings growth exceeds its 5 year annual average (90.6% vs 32.7%). has delivered strong earnings growth in the past 5 years. PROFIT HISTORY $40B USD $ Revenue Profit sciences 7/20

8 10/30/2015 stock analysis infographic Simply Wall St PERFORMANCE LAST YEAR 106.1% Return on Equity 33.5% Return on Assets 50% Return on Captial Industry Average Strong return on shareholders funds (ROE) last year. performed above the Pharma and Biotech industry average based on return on assets (ROA) last year. Performance based on revenue producing assets (ROCE) has been diminishing over 3 years. sciences 8/20

9 10/30/2015 stock analysis infographic Simply Wall St HEALTH 's financial health and their level of debt. NET WORTH $60B Short term Net worth Long term USD Net worth $ Liabilities Assets is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets. 's cash and other short term assets cover its long term commitments. BALANCE SHEET ASSETS LIABILITIES AND SHARES Other Assets Shares Cash + Investments Debt Customers unpaid Physical Assets Inventory Other unpaid Suppliers unpaid sciences 9/20

10 10/30/2015 stock analysis infographic Simply Wall St Low level of unsold assets Total debt is covered by short term assets. HISTORICAL DEBT $25B USD $ Debt Net worth (Equity) The level of debt (130%) compared to net worth is high (greater 40%). The level of debt compared to net worth has increased over the past 5 years (59% vs 130% today). Total debt is well covered by annual operating cash flow (greater than 20% of total debt). Interest on debt is well covered by earnings (27.8x coverage). sciences 10/20

11 10/30/2015 stock analysis infographic Simply Wall St INCOME 's current dividend yield, its volatility and sustainability. ANNUAL DIVIDEND INCOME 1.63% Current annual income from dividends. Estimated to be 1.65% next year. DIVIDEND AMOUNT Paying above low risk savings rate. (1.25%) Paying below the markets top dividend payers. (4.42%) UPCOMING DIVIDEND PAYMENT Purchase on or before the 'Buy Limit' to recieve their next dividend payment. TODAY BUY LIMIT PAYMENT 45 days 16 days 61 days 12/14/ /30/2015 HISTORICAL DIVIDEND YIELD 2% 0% -5 yrs -4 yrs -3 yrs -2 yrs -1 yrs Now Pharma and Biotech Dividends per share have been stable in the past 5 years. Dividends per share have increased over the past 5 years. sciences 11/20

12 10/30/2015 stock analysis infographic Simply Wall St CURRENT PAYOUT TO SHAREHOLDERS FUTURE PAYOUT TO SHAREHOLDERS Paid to you Paid to you 4% Now 16% +3 yrs Retained by Dividends paid are thoroughly covered by net profit (25x coverage). Retained by Dividends after 3 years are expected to be well covered by net profit (6.3x coverage). sciences 12/20

13 10/30/2015 stock analysis infographic Simply Wall St MANMENT 's CEO's compensation, management and board of directors. CEO John Martin $18,957, CEO BIO Dr. John C. Martin, Ph.D. has been the Chief Executive Officer of Inc. since April 1996 and served as its President from April 1996 to May Dr. Martin joined Inc. in October 1990 as Vice President for Research and Development. He had been with Syntex Corporation from 1978 to He served as the President of the International Society for Antiviral Research. He has been Chairman of the Board of Inc., since May He served as the Chairman of California Healthcare Institute from February 2009 to He served as the Chairman of BayBio. Dr. Martin has been a Director of California Healthcare Institute since February 2009 and Gilead Sciences Inc. since April He serves as a Trustee of the University of Southern California. He served as a Director of Gen-Probe Inc. from September 20, 2007 to August 1, He served as a Director of Biotechnology Industry Organization. He served on the National Institute of Allergy & Infectious Diseases Council, Board of Trustees of the University of Chicago, the Board of Trustees of Golden Gate University and the External Scientific Advisory Board of the University of California School of Global Health. He is the Chairman of and Chief Executive Officer of at Gilead Palo Alto, Inc. He served on the Centers for Disease Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, he was inducted into the National Academy of Engineering of the National Academies. Dr. Martin holds a PhD in Organic Chemistry from the University of Chicago and MBA in Marketing from Golden Gate University. CEO sciences 13/20

14 10/30/2015 stock analysis infographic Simply Wall St $20M $0M Total Compensation Salary 's Performance (Relative) CEO's compensation has been consistent with company performance over the past year. CEO's compensation appears reasonable. sciences 14/20

15 10/30/2015 stock analysis infographic Simply Wall St MANMENT TEAM TENURE Average tenure of the management team: 5.6 years The average tenure for the management team is over 5 years, this suggests they are a seasoned and experienced team. MANMENT TEAM Chairman and Chief Executive Officer $18,957, President and Chief Operating Officer $8,261, BOARD OF DIRECTORS Chairman and Chief Executive Officer $18,957, Independent Director $434, Independent Director $429, Independent Director $429, Independent Director $429, Chairperson of Scientific Advisory Board Chief Financial Officer and Executive Vice President $6,223, Chief Scientific Officer and Executive Vice President of Research & Development $6,794, Executive Vice President of Corporate & Medical Affairs and Secretary $5,977, Executive Vice President and General Counsel sciences 15/20

16 10/30/2015 stock analysis infographic Simply Wall St RECENT INSIDER TRADING The number of shares recently bought and sold by management and board of directors. 1 month 3 months 6 months 1 year SOLD BOUGHT insiders have sold more shares than they have bought in the past 3 months. sciences 16/20

17 10/30/2015 stock analysis infographic Simply Wall St COMPANY NEWS ARTICLES, Inc. (GILD) Q3 Earnings: What Went Wrong? ANNOUNCEMENTS Sorry, we couldn't find any announcements or transcripts to display. Bidnessetc 1 day ago Full article, Inc. ( NASDAQ:GILD) reported third quarter fiscal year 2015 (3QFY15) earnings data after markets closed on Tuesday. The biotech giant managed to surpass analysts' expectations in terms of both sales and earnings. Yet shares fell after-hours by 1.34%, causing many to wonder what went wrong. Inc. Q3 Earnings Rise 61% NASDAQ.com 1 day ago Full article (RTTNews.com) - Inc. ( GILD ) released a profit for its third quarter that rose from last year. The company said its bottom line totaled $4.84 billion, or $3.22 per share. This was higher than $3.01 billion, or $1.84 per share, in last year's third quarter. Earnings Whispers:, Inc. (GILD) and Akamai Technologies, Inc (AKAM) Businessfinancenews 1 day ago Full article sciences 17/20

18 10/30/2015 stock analysis infographic Simply Wall St COMPANY INFO DESCRIPTION, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners., Inc. has collaborations with Bristol-Myers Squibb Company, Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California. DETAILS MAP Name: Ticker: GILD Exchange: Founded: 1987 Market Cap: Website: Inc. NasdaqGS $162,087 million Lakeside Drive, Foster City, 94404, United States sciences 18/20

19 10/30/2015 stock analysis infographic Simply Wall St NUMBER OF EMPLOYEES STREET 7, Employees CURRENT STAFF INDUSTRY 7,000 employees. Industry: Sector: Biotechnology Pharmaceuticals, Biotechnology and Life Sciences 2015 SIMPLY WALL STREET PTY LTD, STANDARD & POOR S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED. Simply Wall Street Pty Ltd is a Corporate Authorised Representative of AFSL No Financial services guide (PDF). The information given by Simply Wall St and provided in this web platform is general information only and it does not take into account your investment objectives, financial situation or needs. You should seek independent financial and legal advice to consider if an investment is appropriate for your personal circumstances. Copyright 2015, Standard & Poor s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber s or others use of S&P Capital IQ. (2015) Terms and Conditions, Privacy Policy sciences 19/20

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn

More information

HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio

HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio SECA conference Zurich, 3 July 2013 Dr. Andreas Wicki, CEO HBM at a Glance SIX-listed investment company

More information

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

2 nd Quarter Earnings Conference Call

2 nd Quarter Earnings Conference Call 2 nd Quarter Earnings Conference Call KKR & Co. Inc. Investor Update July 26, 2018 Recent Milestones K-1 $ Converted to a Corporation on July 1, 2018 Investor Day held on July 9, 2018 2 Key Metrics Assets

More information

4 th Quarter Earnings Conference Call

4 th Quarter Earnings Conference Call 4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 8, 2018 4Q17 Reflections Fundamentals Are Strong (Dollars in millions, except per unit amounts and unless otherwise stated)

More information

Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1%

Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% Textron Reports Third Quarter Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% 10/17/ PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported third

More information

Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5%

Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% 07/16/2014 PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported

More information

4 th Quarter Earnings Conference Call

4 th Quarter Earnings Conference Call 4 th Quarter Earnings Conference Call KKR & Co. Inc. Investor Update February 1, 2019 Key Metrics Assets Under Management Management Fees ($ in billions) ($ in millions) $195 $1,069 $168 $905 $100 $107

More information

KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018

KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018 KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018 ($ in trillions) KKR Growth in Alternative Asset Market Share KKR AUM +20% CAGR +21% CAGR Alternative AUM +12% CAGR $190 (1) ($ in billions)

More information

Confirms 2013 Financial Guidance

Confirms 2013 Financial Guidance Confirms 2013 Financial Guidance PROVIDENCE, R.I.--(BUSINESS WIRE)--Jul. 17, 2013-- Textron Inc. (NYSE: TXT) today reported second quarter 2013 income from continuing operations of $0.40 per share, compared

More information

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business

More information

Investor Presentation. November 2018

Investor Presentation. November 2018 Investor Presentation November 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn of Assets $81bn Private Equity, Growth Equity

More information

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA Press release Baar, 28 January 2008 Attractive portfolio of investments in biotech and medical technology to be opened to the public HBM BioVentures announces further information of its planned IPO on

More information

INDUSTRY REPORT for. Thomson Reuters Corporation

INDUSTRY REPORT for. Thomson Reuters Corporation INDUSTRY REPORT for Thomson Reuters Corporation Overview of Thomson Reuters and Business Activities Thomson Reuters Corporation provides intelligent information for companies and individuals seeking competitive

More information

Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

QANTM Intellectual Property Limited (ASX: QIP)

QANTM Intellectual Property Limited (ASX: QIP) QANTM Intellectual Property Limited (ASX: QIP) INFORMATION FOR POTENTIAL INVESTORS KEY INFORMATION Listed: 31 August 2016 Sector: Industrials ASX 200 Weighting: 0% Share Price Range: August 2016 October

More information

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease

More information

1Q 2016 Results. Mermaid Maritime Plc. May 23, 2016

1Q 2016 Results. Mermaid Maritime Plc. May 23, 2016 Mermaid Maritime Plc 1Q 2016 Results May 23, 2016 Disclaimer: The information contained in this document is intended only for use during the presentation and should not be disseminated or distributed to

More information

35 YEARS OF ANALOG INNOVATION 35% NET PROFIT 121 QUARTERS OF POSITIVE CASH FLOW 30 YEARS ON THE NASDAQ 16 YEARS ON THE S&P ANNUAL REPORT

35 YEARS OF ANALOG INNOVATION 35% NET PROFIT 121 QUARTERS OF POSITIVE CASH FLOW 30 YEARS ON THE NASDAQ 16 YEARS ON THE S&P ANNUAL REPORT LINEAR TECHNOLOGY CORPORATION 2016 ANNUAL REPORT 16 YEARS ON THE S&P 500 121 QUARTERS OF POSITIVE CASH FLOW 30 YEARS ON THE NASDAQ 35% NET PROFIT 35 YEARS OF ANALOG INNOVATION Financial Highlights 35 Years

More information

Textron Reports First Quarter 2016 Income from Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook

Textron Reports First Quarter 2016 Income from Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook Textron Reports First Quarter 2016 Income Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook April 20, 2016 06:30 AM Eastern Daylight Time PROVIDENCE, R.I.--(BUSINESS

More information

4 th Quarter Earnings Conference Call

4 th Quarter Earnings Conference Call 4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 9, 2017 Healthy Level of New Capital Raised Year-Over-Year Capital Inflows Driving Asset Growth ($ in billions) $92 +11% $101

More information

Message from the CEO. 4 OMRON Corporation

Message from the CEO. 4 OMRON Corporation Message from the CEO 4 OMRON Corporation Achieving growth through a stronger earnings structure. Solving social issues through new technologies and innovative concepts. Yoshihito Yamada President and CEO

More information

1 st Quarter Earnings Conference Call

1 st Quarter Earnings Conference Call 1 st Quarter Earnings Conference Call KKR & Co. L.P. Investor Update April 27, 2017 1Q17 Reflections Key Business Themes Performance this quarter was strong as our model enabled us to capture more of everything

More information

KKR & Co. L.P. Goldman Sachs U.S. Financial Services Conference: December 6, 2017

KKR & Co. L.P. Goldman Sachs U.S. Financial Services Conference: December 6, 2017 KKR & Co. L.P. Goldman Sachs U.S. Financial Services Conference: December 6, 2017 KKR Growth in Alternative Asset Market Share KKR AUM +20% CAGR Alternative AUM +12% CAGR ($ in trillions) ($ in billions)

More information

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018 Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements

More information

Corporate Profile January 2011 OTCBB:LBMH

Corporate Profile January 2011 OTCBB:LBMH Corporate Profile January 2011 Business Description Liberator Medical Holdings, Inc. s ( Liberator Medical or the Company ) wholly owned subsidiary, Liberator Medical Supply, Inc. is a national direct-to-consumer

More information

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Report on Operations 1999

Report on Operations 1999 Report on Operations 1999 Sales increased 15 percent to MSEK 9,420 Operating income, before items affecting comparability, increased 13 percent to MSEK 1,689 (1,489) Operating income, including capital

More information

4 th Quarter Earnings Conference Call

4 th Quarter Earnings Conference Call 4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 11, 2016 Gross Returns $1B+ Carry Paying Funds Q4 and 2015 Performance Market Indices Private Equity Real Assets Alternative

More information

2,500,000 Shares. Common Stock

2,500,000 Shares. Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-201841 Prospectus Supplement No. 15 to Prospectus dated February 26, 2015 2,500,000 Shares Common Stock This Prospectus Supplement No. 15

More information

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Capcom Co., Ltd. (Tokyo Exchanges, First Section, 9697) 3rd Quarter Report Fiscal year ending March 31, 2016

Capcom Co., Ltd. (Tokyo Exchanges, First Section, 9697) 3rd Quarter Report Fiscal year ending March 31, 2016 Capcom Co., Ltd. (Tokyo Exchanges, First Section, 9697) 3rd Quarter Report Fiscal year ending March 31, 2016 0 Forward-looking Statements Strategies, plans, outlooks and other statements that are not historical

More information

Thelander 2016 PRIVATE COMPANY YEAR END MERIT INCREASE PITCHBOOK REPORT. J. Thelander Consulting

Thelander 2016 PRIVATE COMPANY YEAR END MERIT INCREASE PITCHBOOK REPORT. J. Thelander Consulting Thelander 2016 PRIVATE COMPANY YEAR END MERIT INCREASE PITCHBOOK REPORT J. Thelander Consulting 165 Marlin Mill Valley, CA 94941 jt@jthelander.com jthelander.com +1 415.383.7006 Legal Notice: The Thelander

More information

KOHLBERG CAPITAL CORPORATION. May 2007

KOHLBERG CAPITAL CORPORATION. May 2007 KOHLBERG CAPITAL CORPORATION May 2007 Safe Harbor Statement Private Securities Litigation Reform Act of 1995 Forward Looking Information This presentation may include forward-looking statements. These

More information

New Zealand Oil & Gas Limited has prepared this presentation to provide information about the company.

New Zealand Oil & Gas Limited has prepared this presentation to provide information about the company. Andrew Knight CEO, New Zealand Oil & Gas Ltd Excellence In Oil and Gas Conference Sofitel Sydney Wentworth, 61-101 Phillip Street, Sydney 11.50AM Wednesday, 6 March 2013 Disclaimer New Zealand Oil & Gas

More information

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Capcom Co., Ltd. Tokyo and Osaka Exchanges, First Section, rd Quarter Report Fiscal year ending March 31, 2010

Capcom Co., Ltd. Tokyo and Osaka Exchanges, First Section, rd Quarter Report Fiscal year ending March 31, 2010 Capcom Co., Ltd. Tokyo and Osaka Exchanges, First Section, 9697 3rd Quarter Report Fiscal year ending March 31, 2010 Precautions Concerning Forward-looking Statements Strategies, plans, outlooks and other

More information

Management to Host Conference Call at 8:30 a.m. ET today

Management to Host Conference Call at 8:30 a.m. ET today Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),

More information

Investor Presentation. April 2015

Investor Presentation. April 2015 Investor Presentation April 2015 KKR Global Leader in Alternative Asset Management Private Markets Public Markets Capital Markets Q1 2014 Q1 2015 2 Private Equity Energy $62 bn AUM $37 bn AUM $11.5 bn

More information

For personal use only

For personal use only 2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS) Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor

More information

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014 Sector insights The healthcare market is highly complex with global products delivered through local services and channels. The healthcare value chain is intricate, diverse and interdependent. It is a

More information

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) Feedback from 93 Eastern-European patient groups PUBLISHED JULY 2016 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID

More information

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Joint Democratic and Republican House Policy Committee Hearing August 17, 2016 The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Chairman Benninghoff, Chairman Sturla, and members

More information

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS PHM006K March 2016 Himani Singhi Wadhwa Project Analyst ISBN: 1-62296-254-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform. December 2017

KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform. December 2017 KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform December 2017 Strategic BDC Partnership Introduction On December 11, 2017, KKR and FS Investments

More information

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Phoenix Semiconductor Philippines Corp (PSPC) to be listed on December 1, Semiconductor historical billings report in 000 US$

Phoenix Semiconductor Philippines Corp (PSPC) to be listed on December 1, Semiconductor historical billings report in 000 US$ Report date: November 10, 2014 Phoenix Semiconductor Philippines Corp (PSPC) to be listed on December 1, 2014 Recommendation: Cautious buy with target price of Php 3.81/share At the final offer price of

More information

Form FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007.

Form FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007. Form 51-102FI SERNOVA CORP. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007. The following discussion and analysis should be

More information

KKR & Co. L.P. Morgan Stanley Financials Conference June 2014

KKR & Co. L.P. Morgan Stanley Financials Conference June 2014 KKR & Co. L.P. Morgan Stanley Financials Conference June 2014 DISCLAIMER: This presentation will also contain forward-looking statements, which do not guarantee future events or performance. Please refer

More information

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within

More information

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis

More information

Cherry AB. Investing in a broad gaming portfolio. CEO Anders Holmgren GP Bullhound 6 December 2017

Cherry AB. Investing in a broad gaming portfolio. CEO Anders Holmgren GP Bullhound 6 December 2017 Cherry AB Investing in a broad gaming portfolio CEO Anders Holmgren GP Bullhound 6 December 2017 The game is on Cherry is investing in a broad portfolio of online gaming companies Cherry s strategy is

More information

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market

More information

Greater Yuma EDC Investors Making News

Greater Yuma EDC Investors Making News Greater Yuma EDC Investors Making News May 26, 2016 Issue RCFBH: Mobile Unit Local Seniors Awarded $5K In Scholarships From Alexander Ford Lincoln Johnson Controls Declared A Quarterly Dividend of $0.29

More information

KKR Credit Advisors (Ireland) Unlimited Company PILLAR 3 DISCLOSURES

KKR Credit Advisors (Ireland) Unlimited Company PILLAR 3 DISCLOSURES KKR Credit Advisors (Ireland) Unlimited Company KKR Credit Advisors (Ireland) Unlimited Company PILLAR 3 DISCLOSURES JUNE 2017 1 1. Background The European Union Capital Requirements Directive ( CRD or

More information

ALANCO TECHNOLOGIES INC

ALANCO TECHNOLOGIES INC SECURITIES & EXCHANGE COMMISSION EDGAR FILING ALANCO TECHNOLOGIES INC Form: 8-K Date Filed: 2016-10-04 Corporate Issuer CIK: 98618 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution

More information

NEWS RELEASE. Life sciences companies tout their expertise in India

NEWS RELEASE. Life sciences companies tout their expertise in India For Immediate Release 2014MIT0016-000196 Feb. 19, 2014 NEWS RELEASE International Trade and Responsible for the Asia Pacific Strategy and Multiculturalism Life sciences companies tout their expertise in

More information

The Great Convertible Note Debate What New Angels Need to Know

The Great Convertible Note Debate What New Angels Need to Know The Great Convertible Note Debate What New Angels Need to Know Annarie Lyles (JumpStart NJ Angels, Investor s Circle) Dave Sorin (McCarter & English) Moderator: John Huston Types of Notes Bank Loans Asset

More information

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2016

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2016 Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2016 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements

More information

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in Feature Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia Based on our long-term strategic vision toward 2020, our goal is to become #1 in Asia in terms of our

More information

January September Summary

January September Summary January September 2012 - Summary Consolidated revenue for the period is 60 239 KSEK, up 93% compared to 31 207 KSEK for the same period of 2011. This is in line with the previously communicated forecast

More information

LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)

LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Biotech Concerto #6 Investment Process December 2008

Biotech Concerto #6 Investment Process December 2008 Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision

More information

Q4 & FY18 PERFORMANCE HIGHLIGHTS JUNE 2018

Q4 & FY18 PERFORMANCE HIGHLIGHTS JUNE 2018 Q4 & FY18 PERFORMANCE HIGHLIGHTS JUNE 2018 Index Result Highlights 3 Operational Metrics 7 Financial Summary 10 New product offerings 14 Awards & Accolades 17 Annexure 19 Safe Harbour Statement The documents

More information

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector

More information

Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Voting Procedure (con t)

Voting Procedure (con t) 2 Voting Procedure 1 ( 5 ) One share shall have one vote. A shareholder may cast his/her vote to either approve, disapprove or abstain from voting. Except for Agenda Item 5 regarding election of directors,

More information

Interim Report January March

Interim Report January March Report on 1996 Operations 97 Interim Report January March Continued stable earnings during first quarter of 1997. Higher operating income despite modest decline in sales. Decline in cigarette sales in

More information

Helping People Worldwide Build their Financial Security

Helping People Worldwide Build their Financial Security Invesco Distinctive worldwide investment management capabilities Helping People Worldwide Build their Financial Security Helping People Worldwide Build their Financial Security CP-HK-e-Q209 The size and

More information

Life Sciences Queensland announces latest LSQ Ambassadors

Life Sciences Queensland announces latest LSQ Ambassadors MEDIA RELEASE Monday 22 April, 2013 FOR IMMEDIATE RELEASE Life Sciences Queensland announces latest LSQ Ambassadors (LSQ) is pleased to announce our latest LSQ Ambassadors - two of the life sciences industry

More information

Life Sciences Tools, Diagnostics, & Services Q Industry Overview

Life Sciences Tools, Diagnostics, & Services Q Industry Overview Life Sciences Tools, Diagnostics, & Services Q4 2017 Industry Overview Life Sciences Tools, Diagnostics, & Services: Industry Overview Key Takeaways M&A activity has remained steady at high volumes of

More information

NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations

NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and

More information

Open Forum. Newton Glassman, Executive Chairman & CEO David Reese, President & COO. October 13, 2015

Open Forum. Newton Glassman, Executive Chairman & CEO David Reese, President & COO. October 13, 2015 Open Forum Newton Glassman, Executive Chairman & CEO David Reese, President & COO October 13, 2015 Note: Callidus financials reflect most recent publicly released data (Q2 earnings, August 2015) 1 Welcome

More information

Omeros Raises More Than $63 Million in Financing

Omeros Raises More Than $63 Million in Financing Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,

More information

BOARD OF DIRECTORS. PETER WEHRLY Chair

BOARD OF DIRECTORS. PETER WEHRLY Chair BOARD OF DIRECTORS PETER WEHRLY Chair Peter Wehrly is the former group president of developed markets at Covidien, the manufacturer of medical devices with sales of over $10.7 billion (2014). Peter held

More information

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D. Discovery: From Concept to the Patient - The Business of Medical Discovery Todd Sherer, Ph.D. Associate Vice President for Research and Director of OTT President Elect, Association of University Technology

More information

Analysts Ideas of the Week CardioComm Solutions - ECG Software Management

Analysts Ideas of the Week CardioComm Solutions - ECG Software Management Week of August 29, 2016 Analysts Ideas of the Week CardioComm Solutions - ECG Software Management www.researchfrc.com Sid Rajeev, B.Tech, MBA, CFA Head of Research CardioComm Solutions - ECG Software Management

More information

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

S&P Global Market Intelligence, KPMG and ACG

S&P Global Market Intelligence, KPMG and ACG S&P Global Market Intelligence, KPMG and ACG Complimentary Webinar June 7, 2016 Permission to reprint or distribute any Permission content to from reprint this or presentation distribute any requires content

More information

Overview of Venture Equity

Overview of Venture Equity Overview of Venture Equity SVB Analytics Report 2017 Written by SVB Analytics: Steve Liu Managing Director sliu@svb.com Sean Lawson Senior Manager slawson2@svb.com Steven Pipp Senior Associate spipp@svb.com

More information

An Uneven Planet. Globalization, Capital, & Inequality in the 21 st Century

An Uneven Planet. Globalization, Capital, & Inequality in the 21 st Century An Uneven Planet Globalization, Capital, & Inequality in the 21 st Century Today s Discussion Brief Review Globalization The Problem of Inequality Picketty & the Politics of Redistribution Brief Review

More information

GENDER PAY GAP REPORT

GENDER PAY GAP REPORT WRAFTON LABORATORIES GENDER PAY GAP REPORT APRIL 2017 Introduction Wrafton Laboratories Limited is part of Perrigo, a global pharmaceutical company that provides Quality Affordable Healthcare Products

More information

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector Publishing Intelligence Limited

More information

New Rhein concludes successful investment in Chase Pharmaceuticals via sale to Allergan

New Rhein concludes successful investment in Chase Pharmaceuticals via sale to Allergan New Rhein concludes successful investment in Chase Pharmaceuticals via sale to Allergan NEWS PROVIDED BY New Rhein Healthcare Investors LLC Nov 22, 2016, 04:57 ET CHICAGO, Nov. 22, 2016 /PRNewswire/ --

More information

MASTERCARD INC FORM 8-K. (Current report filing) Filed 09/11/08 for the Period Ending 09/09/08

MASTERCARD INC FORM 8-K. (Current report filing) Filed 09/11/08 for the Period Ending 09/09/08 MASTERCARD INC FORM 8-K (Current report filing) Filed 09/11/08 for the Period Ending 09/09/08 Address 2000 PURCHASE STREET PURCHASE, NY 10577 Telephone 9142492000 CIK 0001141391 Symbol MA SIC Code 7389

More information

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Annual Press Conference Financial year 2017

Annual Press Conference Financial year 2017 Annual Press Conference 2018 Financial year 2017 Financial year Hubertus von Baumbach Chairman of the Board of Managing Directors 2017 Highly successful financial year 2017 Major success with human pharmaceuticals

More information

Igor Fisch. New candidate, independent

Igor Fisch. New candidate, independent Igor Fisch New candidate, independent Igor Fisch is a co-founder of Selexis SA, a biotech company based in Switzerland. He grew the company from inception to profits in less than 5 years with up to > 5MCHF

More information

Activision Announces Second Quarter 2006 Results

Activision Announces Second Quarter 2006 Results Activision Announces Second Quarter 2006 Results - Company's Q2 Results Exceed Outlook - - Company Increases FY 2006 Revenue Outlook - SANTA MONICA, Calif., Nov 02, 2005 /PRNewswire-FirstCall via COMTEX

More information

Investor Presentation & Financial Highlights. November 2018

Investor Presentation & Financial Highlights. November 2018 Investor Presentation & Financial Highlights November 2018 Forward Looking Statements Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties.

More information

State of Licensing 2011 Update

State of Licensing 2011 Update State of Licensing 2011 Update Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol-

More information

Global Pharmaceuticals

Global Pharmaceuticals ROSENFIELD PR OGR AM in public affairs, international relations, and human rights Global Pharmaceuticals February 3 5, 2009 GRINNELL COLLEGE Global Pharmaceutical Symposium February 3-5, 2009 Tuesday,

More information

Textron Reports Third Quarter 2018 Results; Narrows Full-Year EPS and Cash Guidance

Textron Reports Third Quarter 2018 Results; Narrows Full-Year EPS and Cash Guidance Corporate Communications Department NEWS Release Textron Reports Third Quarter 2018 Results; Narrows Full-Year EPS and Cash Guidance $468 million returned to shareholders through share repurchases Completed

More information

CATALENT PHARMA SOLUTIONS, INC.

CATALENT PHARMA SOLUTIONS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

Venture Capital Search Highlights

Venture Capital Search Highlights Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more

More information

1h Fenwick. Trends in Terms of U.S. Life Science Venture Financings. First Half fenwick & west llp

1h Fenwick. Trends in Terms of U.S. Life Science Venture Financings. First Half fenwick & west llp 1h 2012 Trends in Terms of U.S. Life Science Venture Financings First Half 2012 Fenwick fenwick & west llp 1h 2012 Trends in Terms of U.S. Life Science Venture Financings First Half 2012 Survey Introduction

More information

Announcement of the US Business Restructuring

Announcement of the US Business Restructuring August 15, 2018 Shin Nippon Biomedical Laboratories, Ltd. (The First Section of the Tokyo Stock Code Number: 2395) Representative: Chairman and President Ryoichi Nagata C o n t a c t : Senior Executive

More information

2003 ANNUAL REPORT TOOLS FOR NANOTECH

2003 ANNUAL REPORT TOOLS FOR NANOTECH 2003 ANNUAL REPORT TOOLS FOR NANOTECH FEI REVENUES In Millions of Dollars 400 350 300 250 200 150 100 50 94 95 96 97 98 99 00 01 02 03 OPERATING INCOME In Millions of Dollars 60 50 40 30 20 10 0 94 95

More information

PATENT PROPERTIES ANNOUNCES SECOND QUARTER 2015 RESULTS. Announces Name Change to Walker Innovation Inc.

PATENT PROPERTIES ANNOUNCES SECOND QUARTER 2015 RESULTS. Announces Name Change to Walker Innovation Inc. PATENT PROPERTIES ANNOUNCES SECOND QUARTER 2015 RESULTS Announces Name Change to Walker Innovation Inc. Announces Name Change of its United States Patent Utility Service to Haystack IQ Trial Usage of New

More information